Form 4: Abbott Laboratories Director John G. Stratton Reports Acquisition of Stock Equivalent Units

Director John G. Stratton reports acquiring 323 stock equivalent units of Abbott Laboratories on March 31, 2024, through director fees credited to a grantor trust.

Summary

• John G. Stratton, a director of Abbott Laboratories, reported acquiring 323 stock equivalent units on March 31, 2024.
• These units were obtained through director fees credited to a stock equivalent unit account under a grantor trust.
• The price per unit is $113.66.
• Stratton's total holdings after the transaction amount to 10,486 stock equivalent units.
• These units earn the same return as if the fees were invested in Abbott shares and are generally paid out in cash at age 65 or upon retirement from the board.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. It reflects a routine transaction indicating continued director investment in the company, which is generally viewed favorably.

Positives

• The acquisition of stock equivalent units demonstrates the director's continued investment in Abbott Laboratories.
• The structure of the stock equivalent unit account aligns the director's interests with those of the shareholders.

Future Outlook

The stock equivalent units will continue to accrue value based on the performance of Abbott shares and will be paid out in cash upon retirement or at age 65.

Industry Context

This filing is a routine disclosure related to director compensation and holdings, common among publicly traded companies. It reflects a mechanism for aligning director interests with shareholder value through equity-based compensation.

Comparison to Industry Standards

• Equity-based compensation for directors is a common practice among large publicly traded companies like Abbott Laboratories.
• Companies such as Johnson & Johnson, Pfizer, and Merck also utilize stock options, restricted stock units, or similar instruments to incentivize and reward their board members.
• The specific terms of these arrangements, such as vesting schedules and payout conditions, can vary widely based on company policy and individual agreements.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it aligns the director's interests with the company's performance.

Key Dates